Therapeutic targets and new directions for antibodies developed for ovarian cancer.

MAbs

a St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London& NIHR Biomedical Research Center at Guy's and St. Thomas' Hospital and King's College London, Guy's Hospital, King's College London, London , UK.

Published: November 2017

Antibody therapeutics against different target antigens are widely used in the treatment of different malignancies including ovarian carcinomas, but this disease still requires more effective agents. Improved understanding of the biological features, signaling pathways, and immunological escape mechanisms involved in ovarian cancer has emerged in the past few years. These advances, including an appreciation of the cross-talk between cancer cells and the patient's immune system, have led to the identification of new targets. In turn, potential antibody treatments with various mechanisms of action, including immune activation or toxin-delivery, that are directed at these targets have been developed. Here, we identify established as well as novel targets for antibodies in ovarian cancer, and discuss how they may provide fresh opportunities to identify interventions with enhanced therapeutic potential.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098446PMC
http://dx.doi.org/10.1080/19420862.2016.1219005DOI Listing

Publication Analysis

Top Keywords

ovarian cancer
12
therapeutic targets
4
targets directions
4
directions antibodies
4
antibodies developed
4
ovarian
4
developed ovarian
4
cancer
4
cancer antibody
4
antibody therapeutics
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!